Skip to main content
. 2022 Jan 31;9(1):e000763. doi: 10.1136/bmjgast-2021-000763

Table 3.

Primary and secondary outcomes

Variable N Inpatient
n=695
Ambulatory, n=69 P value
Ambulatory from diagnosis, n=15 Initially inpatient and then discharged to ambulatory, n=54
Primary outcome
Colectomy during index ASUC management period 764 15.0% (104/695) 13.3% (2/15) 13.0% (7/54) 0.95
Secondary outcomes
Admitted to hospital during treatment 764 99.9% (694/695) 40.0% (6/15) 100.0% (54/54) 0.0005
Corticosteroid therapy
Received intravenous corticosteroids
 Yes 758 97.4% (672/690) 100.0% (15/15) 100.0% (53/53) 0.74
 No (straight to biologic) 2.6% (18/690) 0.0% (0/15) 0.0% (0/53)
Type of intravenous corticosteroid
 Hydrocortisone (intravenous) 740 87.6% (589/672) 20.0% (3/15) 79.2% (42/53) 0.0005
 Methylprednisolone (intravenous) 740 12.4% (83/672) 80.0% (12/15) 20.8% (11/53)
Responded to corticosteroids 753 71.6% (490/684) 66.7% (10/15) 75.9% (41/54) 0.74
Rescue/primary induction therapy
Received rescue/primary induction therapy 751 40.9% (281/687) 60.0% (9/15) 36.7% (18/49) 0.28
Time to rescue/primary induction therapy (days) 286 6.0 (4.0–8.0) 3.5 (2.0–5.2) 5.0 (4.5–6.0) 0.19
Responded to rescue/primary induction treatment 301 80.4% (221/275) 62.5% (5/8) 88.9% (16/18) 0.26
Surgery
Time to colectomy (days) 112 12.0 (7.0–21.0) 16.0 (14.0–43.5) 6.0 (3.5–13.0) 0.15
Mortality 754 1.2% (8/686) 0.0% (0/15) 0.0% (0/53) 1
Duration of hospital treatment (days)* 695 7.0 (5.0–13.0) 6.0 (6.0–18.0) 7.0 (5.0–9.0) 0.47

P value=Fisher’s exact test or Kruskal-Wallis test for discrete and continuous variables continuous, respectively. Discrete variables displayed % (n/N) and continuous variables median (IQR).

*Only patients with ambulatory care from diagnosis who were admitted to hospital (n=6) had inpatient stay data captured.

ASUC, acute severe ulcerative colitis.